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Background and objectives: Esophageal cancer incidence is gradually increasing worldwide. Studies have
looked at the pathological stage rather than clinical stage as predictor of survival. We looked at patients
with complete pathological response to compare their survival outcomes to those who had residual
disease after neoadjuvant treatment.
Materials and methods: All patients with esophageal cancer who underwent neoadjuvant treatment
followed by resection at our institute were retrospectively reviewed. Overall survival and disease free
survival were calculated for patients with complete pathological response and compared to those with
residual disease using log rank test.
Results: Mean age of our patients was 51.08 years with standard deviation of 10.17 years. 39% belong to
stage IIa while 5% belong to Stage IIb. 56% were Stage III. Final histopathological stage was recorded and
both disease free and overall survival were calculated. 45% of our patients had complete pathological
response. Patients with complete pathological response had mean survival of 62.73 months  17.02
compared to 41.42 months for patients who had residual disease. 5 year disease free survival was 58%.
Conclusion: Complete Pathological response signiﬁcantly improves overall and disease free survival. It is
also the predictor of long term survival.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Esophageal cancer incidence is gradually increasing worldwide
[1]. It is an aggressive disease with 5 year survivals of less than 25%
for all stages [2]. There is great interest in neoadjuvant treatment
for esophageal cancer, but there is no clear survival advantage and
majority of studies have been criticized for ﬂawed designs [3,4].
With the availability of endoscopic ultrasound, better CAT scanners
and PET/CT; there is improvement in reliability of clinical staging
but still there is difference between clinical and pathological stage
of disease making it difﬁcult to predict survival on the basis of
clinical stage. Studies have looked at the pathological stage rather
than clinical stage as predictor of survival. However only 20e30%
patients who show complete pathological response indicate better
long term and disease free survival [5e8].author.
hrizwi@live.com (F.H. Rizvi).
by Elsevier Ltd. All rights reservedSo far there are no tools to tell us with surety that there is no
residual disease after chemoradiotherapy. So patients require
esophagectomy as part of standard treatment. Randomized
control trials with long term follow up are lacking for patients
who do show response and do not undergo esophagectomy
[6,9].
We are the only tertiary care cancer hospital in Pakistan. We
generally encounter esophageal cancer at locally advanced stage
and offer neoadjuvant treatment. We looked at our data to assess
the response of patients to neoadjuvant treatment and speciﬁcally
looked at patients with complete pathological response to compare
their survival outcomes to those who had residual disease.2. Objective
To determine if complete pathological response in locally
advanced esophageal cancer, predicts long term survival after
neoadjuvant treatment..
Table 2
Surgical intervention and treatment response.
N N %
Surgical procedure
Transhiatal 58/100 58%
Minimally invasive 33/100 33%
Open three stage 9/100 09%
Type of neoadjuvant
Chemoradiotherapy 95/100 95%
Chemotherapy 05/100 05%
Treatment response
No change 14/100 14%
Decrease in disease stage 33/100 33%
Progression of disease 08/100 08%
Pathological complete response 45/100 45%
Margin status
R0 97/100 97%
R1 03/100 03%
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All patients with esophageal cancer who underwent neo-
adjuvant treatment followed by resection at our institute from
January 2005 to December 2011 were retrospectively reviewed.
Patients were staged according to AJCC staging system using EUS
and CAT scan as primary staging modalities. All patients were dis-
cussed in multidisciplinary team meeting and treatment plan was
decided. Patients assigned for neoadjuvant treatment followed by
surgery were selected for review. Patients with irresectable disease
and planned for palliative treatment were excluded. A total of 109
patients were identiﬁed, out of which 4 required emergency sur-
gery while 5 had missing data for analysis. We were left with 100
patients who completed neoadjuvant treatment and were there-
fore selected for ﬁnal analysis (see Table 1).
Patient medical records were analyzed, and information was
collected into an esophageal database. Variables recorded include
epidemiological factors (age, comorbidities and symptoms) treat-
ment factors (type of chemotherapy and dose of radiation), tumor
factors (histology, clinical stage, pathologic stage, and complete-
ness of resectiondR0, R1, or R2), operative and hospital course
factors (operation performed, duration of procedure, blood loss,
type of anastomosis, and complications), and tumor recurrence and
long-term survival.
Patients received external beam radiation between 45 and 55 Gy
with concurrent cisplatin and 5FU. Patients were restaged with CAT
scan after 4 weeks of completing neoadjuvant treatment and were
then planned for surgery depending on the resectability status.
Patients with metastasis or T4b disease were not offered surgery.Table 1
Patient and tumor characteristics.
N ¼ 100 N %
Age 51.08  10.17
Gender
Male 52/100 52%
Female 48/100 48%
Comorbidity 18/100 18%
Site
Mid thoracic 26/100 26%
Lower thoracic 67/100 67%
GE junction 7/100 7%
Histology
Squamous cell ca 76/100 76%
Adenocarcinoma 24/100 24%
Grade
Well differentiated 15/100 15%
Moderately differentiated 57/100 57%
Poorly differentiated 28/100 28%
Clinical T stage
T1 0/100 0%
T2 8/100 8%
T3 76/100 76%
T4a 16/100 16%
Clinical N stage
N0 43/100 43%
N1 57/100 57%
Clinical stage
I 0/100 0%
IIA 39/100 39%
IIB 05/100 5%
III 56/100 56%
IV
Pathological stage
Complete response 45/100 45%
I 03/100 3%
IIa 25/100 25%
IIb 18/100 18%
III 09/100 9%
IV 0/100 0%Patients were followed quarterly for ﬁrst 2 years and then semi-
annually for 1 year and yearly thereafter till completion of 5
years. Patients required CAT scan every year to look for any radio-
logical evidence of recurrence. Frequencies and percentages were
calculated for categorical datawhilemeanswith standard deviation
were calculated for continuous variables. Chi square, Fischer’s exact
test and t test were applied and p value of less than 0.05 was
considered statistically signiﬁcant. Overall survival was calculated
from the time of diagnosis till death while disease free survival was
calculated from the time of surgery till documented recurrence
(either radiological or histopathology proven) using Kaplan Meir
survival curves. Patients with complete pathological response on
histopathology specimen were compared to those having residual
disease both for overall and disease free survival and log rank test
applied to evaluate signiﬁcance. All data was analyzed in SPSS
version 19 (see Table 2).
4. Results
Mean age of our patients was 51.08 years with standard devia-
tion of 10.17 years. Gender distribution was comparable. Preoper-
ative staging of patients were performed using EUS and CAT scan of
chest and abdomen. 39% belong to stage IIa while 5% belong to
Stage IIb. 56% were Stage III. Major histopathological diagnosis was
squamous cell carcinoma. All patients received neoadjuvant treat-
ment, 95% received chemoradiotherapy while 5% received chemo-
therapy alone. Patients receiving chemotherapy alone were those
having GEJ tumors. 85% of our patients received cisplatin and 5FU
along with 45 Gy of radiotherapy. Patients were restaged 4 weeks
post completion of neoadjuvant treatment to assess response. Pa-
tients then underwent surgical intervention, if resectable on post
treatment scan. 58% of our patients underwent transhiatal esoph-
agectomy while 34% underwent minimally invasive esoph-
agectomy, rest had open three stage procedure. All patients had
cervical anastomosis and gastric tube placed in posterior medias-
tinum. Anastomosis was made hand sewn, single layer using pro-
lene 4/0. Final histopathological stage was recorded and both
disease free and overall survival were calculated. 45% of our pa-
tients had complete pathological response. Overall mean survival
for all stages was 51.86 months  9.87 months (median is 44
months), with 5 year survival of 38%. When analyzed according to
histopathological response, patients with complete pathological
response had mean survival of 62.73 months  17.02 (median is 68
months) compared to mean survival of 41.42 months (median is 29
months) for patients who had residual disease. Log rank test
showed p value of 0.007. There were 26 recurrences of which 5
were local, 14 were in regional nodes and 7 were distant. Overall
Fig. 1. Overall survival for all stages.
Fig. 3. Survival comparison for pathological complete response versus residual disease
patients. Log rank test was statistically signiﬁcant.
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months) which againwhen compared was 73.96 6.96 months for
patients who had complete pathological response compared to
44  6.87 months in patients who had residual disease on histo-
pathological specimen. This was also statistically signiﬁcant. 5 year
disease free survival was 58%. Our recurrence rate was 26%, with
majority of these occurring in patients with residual disease as
shown in (Figs. 1e4).
There were 5 local recurrences of which only 1 occurred in a
patient with complete pathological response while 4 occurred in
patients with residual disease. Similarly there were 14 regional
recurrences of which 6 occurred in patients with complete patho-
logical response while 8 occurred in patients with residual disease
(see Table 3).
There were 7 distant recurrences which all occurred in patients
with residual disease. Most of our patients had regional recurrences
to cervical, mediastinal or celiac axis nodes while most common
site for distant recurrence was liver and bone. Patients with disease
recurrence had signiﬁcantly poor survival outcome.Fig. 2. Disease free survival for all stages.5. Discussion
Preoperative chemoradiotherapy for esophageal cancers has
shown signiﬁcant improvement in both overall and disease free
survival. Hagen et al. in a randomized controlled trial of 368 pa-
tients reported median overall survival of 49.4 months in neo-
adjuvant treatment group versus 24months in surgery alone group.
This trial is the ﬁrst to show statistically signiﬁcant survival in two
treatment regimens [10]. Pathological complete response is the
only predictor of long term survival as shown in previous studies.
We are using neoadjuvant treatment for Stage II and III esoph-
ageal cancers. There are no studies from Pakistan reporting their
experience for neoadjuvant treatment in esophageal cancer. We
retrieved our data to assess if pathological complete response does
predict statistically signiﬁcant improvement in overall and disease
free survival.
In our study of 100 patients with locally advanced esophageal
cancer, we have shown that preoperative clinical characteristicsFig. 4. Disease free survival comparison for patients with complete pathological
response versus those with residual disease. Log rank test was statistically signiﬁcant.
Table 3
Site of recurrence with break up of disease. Recurrence according to pathological
response (pCR). Total recurrences were 26. Patients with complete pathological
response had only 1 local recurrence while there were 6 regional and no distant
recurrences.
Site of recurrence N pCR Residual disease
Local 05/26 1/5 4/5
Regional 14/26 6/14 8/14
Distant 07/26 0/7 7/7
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show statistically signiﬁcant survival advantage. 45% of our patients
with complete pathological response in neoadjuvant treatment
group were slightly better to what is shown in other studies by
Chirieac et al. and Meredith et al. There was no difference in type of
chemotherapy used and response rates. Only 15% of our patients
received carboplatin based chemotherapy and the reason for use
cannot be ascertained due to retrospective nature of our review
[6,11].
Our overall survival of 38% at 5 years and 32% at 8 years for
locally advanced esophageal cancers is comparable to that pub-
lished by other studies. Patients with complete pathological
response had overall survival of 53% compared to 22% for patients
with residual disease. This is again similar to results published by
Meredith et al. which showed 5 year survival of 52% with pCR.
Chirieac et al. did show 5 year survival of 65% in patients with
complete pathological response and 29% in patients with residual
disease, which is slightly better to survival outcomes in other
studies. Other studies have also shown signiﬁcantly improved
overall survival for patients with pathological complete response
[12,13].
5 year disease free survival in our study was 58%. This is 73% for
pCR compared to 44% for patients with residual cancers. Berger
et al. in his study showed 5 year disease free survival of 49% which
was better in pCR group 62% compared to 31% for residual Stage II
or higher group. Other studies have also shown similar disease free
survival. In his study Berger et al. has combined patients with pCR
to those which showed signiﬁcant response to neoadjuvant treat-
ment and now had Stage I disease on ﬁnal histopathology that
might have resulted in lower disease free survival in his study [14].
We did not encounter clinical stage, diagnosis, comorbid con-
ditions and type of surgical intervention to signiﬁcantly impact
overall or disease free survival thereby pCR was the only predictor
of long term survival in patients with esophageal cancer. This
observation is similar to what has been observed in other studies.
Discussion is now ongoing on how to assess complete response
to neoadjuvant treatment and to avoid surgery in these patients.
Also to see if excluding esophagectomy has an impact on long term
survival. So far focus is on PET/CT to predict response to treatment
and various studies have shown a wide range of sensitivity and
speciﬁcity for PET to predict response. Webber and his colleagues
have shown PET scan to be 93% sensitive and 95% speciﬁc in pre-
dicting response to neoadjuvant treatment however McLoughlin
et al. has shown sensitivity of 61.8% while speciﬁcity of 43.8%.
Similar results have been shown by Luketich et al. With such wide
range of experience in predicting response to treatment, esoph-
agectomy as yet should not be excluded from treatment paradigm.
Studies have reported higher rate of recurrence if esophagectomy is
excluded and long term follow up is lacking [15,16].
Our study has limitation of being retrospective review so we
lack insight into why different treatment regimens were used in
various patients and also what was the morbidity of neoadjuvant
treatment. We also cannot determine why some patients did not
complete predetermined treatment protocol. We have contacted allpatients at the end of this study to determine their status and have
censored any patient with whom contact could not be established,
from the survival analysis. We have reported all patients who have
completed our predeﬁned treatment protocol and thereby study
lacks on the part of patients who never completed the treatment
and what their outcome would be. We have tried our best to report
data without any bias but retrospective nature of data may add
some bias.
6. Conclusion
In our study we have shown that pathological complete
response signiﬁcantly improves overall and disease free survival
and is the predictor of long term survival. More studies are needed
to assess what factors determine tumor response to neoadjuvant
treatment. With better understanding of tumor biology and more
advanced targeted therapies we might get better pCR in the future.
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